Understanding Inherited Retinal Diseases: Types & Symptoms

Inherited retinal diseases (IRDs) comprise over 200 genetic disorders causing progressive vision loss. Early genetic diagnosis guides prognosis, family counseling, and emerging therapies.

Major IRD Types

Retinitis Pigmentosa (RP)

Most common IRD. Rod‑cone degeneration → night blindness, peripheral field loss → tunnel vision. Onset childhood to mid‑adulthood. Many genes (e.g., RHO, RPGR, USH2A).

Usher Syndrome

RP + sensorineural hearing loss. Three clinical types (1–3) by severity/onset. Genes: MYO7A, USH2A, CLRN1, others.

Stargardt Disease

Juvenile macular degeneration. ABCA4 mutations → lipofuscin accumulation → central vision loss, color deficits. Onset typically childhood/teen years.

Leber Congenital Amaurosis (LCA)

Severe infantile blindness/visual impairment. Nystagmus, sluggish pupils, eye‑pressing. >25 genes (RPE65, CEP290, GUCY2D). Gene therapy (voretigene neparvovec) approved for RPE65‑LCA.

Cone‑Rod Dystrophy

Cone degeneration first → central/color vision loss, photophobia; later rod involvement → night blindness. Genes: ABCA4, GUCY2D, CRX.

Macular Dystrophies

Group affecting macula: Best disease (BEST1), pattern dystrophies, Sorsby fundus dystrophy. Central vision loss, often mid‑life onset.

Choroideremia

X‑linked (CHM gene). Choroidal degeneration → night blindness, peripheral loss → legal blindness by mid‑adulthood. Males affected; female carriers may have mild signs.

Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL)

Rare, autosomal dominant (TREX1). Retinal vascular loss + brain white matter lesions → visual field defects, stroke‑like episodes, cognitive decline.

Mitochondrial Disorders

Mitochondrial DNA mutations (e.g., MELAS, LHON) can include retinal degeneration among multi‑system features.

Diagnosis & Next Steps

  • Clinical exam + imaging (OCT, autofluorescence, ERG, visual fields)
  • Genetic testing (panel, exome, genome) identifies causative variant in ~60–80%.
  • Genetic counseling for inheritance pattern, recurrence risk, family screening.
  • Clinical trial eligibility often requires molecular diagnosis.
  • Low‑vision rehabilitation maximizes function at every stage.

Rapid advances in gene therapy, optogenetics, and cell replacement offer hope for previously untreatable IRDs.

Eye & Vision Disorders - Related Articles